Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $668,625.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 12,500 shares of the business's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $53.49, for a total transaction of $668,625.00. Following the sale, the insider now owns 169,721 shares of the company's stock, valued at approximately $9,078,376.29. The trade was a 6.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Timothy Rolph also recently made the following trade(s):

• On Tuesday, June 10th, Timothy Rolph sold 2,358 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.00, for a total transaction of $127,332.00.
• On Friday, June 6th, Timothy Rolph sold 25,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $55.04, for a total value of $1,376,000.00.
• On Tuesday, May 6th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $43.43, for a total value of $542,875.00.
• On Thursday, April 24th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The stock was sold at an average price of $41.03, for a total transaction of $256,437.50.
• On Monday, April 7th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The shares were sold at an average price of $35.88, for a total transaction of $224,250.00.

Akero Therapeutics Stock Up 1.1%

Akero Therapeutics stock traded up $0.60 during mid-day trading on Thursday, hitting $53.56. 1,573,450 shares of the company's stock were exchanged, compared to its average volume of 1,001,064. Akero Therapeutics, Inc. has a 1-year low of $21.02 and a 1-year high of $58.40. The stock has a 50 day moving average of $43.18 and a two-hundred day moving average of $39.98. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. The stock has a market cap of $4.27 billion, a P/E ratio of -14.28 and a beta of -0.16.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.01) by $1.91. As a group, analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on AKRO shares. Citigroup cut their price objective on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Bank of America raised their target price on shares of Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research note on Tuesday, May 27th. HC Wainwright upped their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Monday, March 3rd. Finally, Morgan Stanley reiterated an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $82.50.

Institutional Investors Weigh In On Akero Therapeutics

A number of large investors have recently added to or reduced their stakes in AKRO. RTW Investments LP raised its position in shares of Akero Therapeutics by 15.9% in the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock valued at $190,840,000 after purchasing an additional 940,388 shares during the period. Deep Track Capital LP lifted its stake in shares of Akero Therapeutics by 116.0% in the fourth quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock worth $41,452,000 after buying an additional 800,216 shares during the last quarter. Balyasny Asset Management L.P. bought a new stake in shares of Akero Therapeutics during the 4th quarter worth $18,059,000. SG Americas Securities LLC grew its stake in Akero Therapeutics by 93.3% in the 1st quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company's stock valued at $46,786,000 after buying an additional 557,794 shares during the last quarter. Finally, Lord Abbett & CO. LLC bought a new position in Akero Therapeutics in the 1st quarter worth $21,333,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.